Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

• Published in: Journal of the European Academy of Dermatology and Venereology 2023-01, Vol.37 (1), p.57-64
• Main Authors: Muniesa, Cristina, Gallardo, Fernando, García‐Doval, Ignacio, Estrach, M. Teresa, Combalia, Andrea, Morillo‐Andújar, Mercedes, De la Cruz‐Vicente, Fátima, Machan, Salma, Moya‐Martínez, Cristina, Rovira, Roger, Sanchez‐Gonzalez, Blanca, Acebo, Elvira, Amutio, Elena, Peñate, Yeray, Losada‐Castillo, Maria del Carmen, García‐Muret, M. Pilar, Iznardo, Helena, Román‐Curto, Concepción, Cañueto, Javier, Fernández‐de‐Misa, Ricardo, Flórez, Ángeles, Izu, Rosa María, Torres‐Navarro, Ignacio, Zayas, Ana, Pérez‐Paredes, Gema, Blanes, Mar, Yanguas, J. Ignacio, Pérez‐Ferriols, Amparo, Callejas‐Charavia, Marta, Ortiz‐Romero, Pablo Luis, Pérez‐Gil, Amalia, Prieto‐Torres, Lucia, González‐Barca, Eva, Servitje, Octavio
• Format: Article
• Language: English
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.18563

ABSTRCT Background Brentuximab vedotin (BV) has been approved for CD30‐expressing cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results Sixty‐seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty‐eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow‐up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow‐up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions These results confirm the efficacy and safety of BV in patients with advanced‐stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.